(Q50575393)

English

Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin

scientific article published in October 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

1 reference

based on heuristic

inferred from title

N-Terminal Propeptide of Type III Collagen

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Trocme C

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Leroy V

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Sturm N

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Hilleret MN

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Bottari S

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Morel F

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Zarski JP

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

13

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

643-651

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Prothrombin index is an indirect marker of severe liver fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Dose effects of growth hormone during puberty

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00730.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2006.00730.X

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/16970595

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50575393&oldid=2253335820"